Dr. Todd’s extensive experience in developing diverse biotherapeutic modalities and small molecules for oncology, in addition to her experience with a variety of biologic modalities, will be a great resource for our clients developing biotherapeutic and oncology products.
ROCHELLE, Va. (PRWEB) December 04, 2019
NDA Partners Chairman Carl Peck, MD, announced today that Dr. Marque Todd, a regulatory toxicology expert with more than 20 years of experience working in the biopharmaceutical industry, has joined the firm as an Expert Consultant.
Dr. Todd has extensive experience with a variety of biologic modalities including monoclonal antibodies, bi-specific antibodies, Fc and other fusion proteins, antibody-drug conjugates, cytokines/interleukins, protein replacement therapies, nanoparticles, CAR-T cells, and vaccines. She also has extensive experience in developing diverse biotherapeutic modalities and small molecules for oncology. Dr. Todd has been involved in the preparation and submission of nonclinical sections of early and late stage regulatory documents including INDs and BLAs/NDAs and has participated in numerous successful health authority meetings.
Prior to joining NDA Partners, Dr. Todd was a Research Fellow at Pfizer and served as a Principal Scientist at Amgen and Chiron. In addition to her industry roles, Dr. Todd served as an Adjunct Professor with the University of California San Diego Extension, where she co-taught a course on nonclinical toxicology and drug development with sessions focused on the nonclinical development of biotherapeutics and oncology products.
“Dr. Todd’s extensive experience in developing diverse biotherapeutic modalities and small molecules for oncology, in addition to her experience with a variety of biologic modalities, will be a great resource for our clients developing biotherapeutic and oncology products,” said Dr. Peck. “We are pleased to welcome her to NDA Partners.”
Dr. Todd received her Doctor of Veterinary Medicine from Colorado State University and a master’s degree in Cancer Biology from Harvard School of Public Health, where she also completed postdoctoral work in molecular biology and immunology. Dr. Todd is a Diplomate of the American Board of Toxicology.
About NDA Partners
NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.
Earle Martin, Chief Executive Officer